Ind-Swift Laboratories has received approval from the Japanese Government's pharmaceutical and medical devices agency (PMDA) for the supply of Pioglitazone and Risedronate Sodium from its manufacturing facilities at Derabassi in Punjab. With the approval, the company targets a market share of 15-20 per cent for these products by 2013.
The market for Pioglitazone, an anti-diabetic drug, is estimated at about $2.8 billion while that of Risedronate Sodium, a drug for Osteoporosis, is pegged at $1.6 billion. The company has already filed four DMFs (drug master files) in Japan including that of Atorvastatin, which commands a $12 billion market. It expects PMDA approval soon. It has filed 302 DMFs so far with various regulatory authorities.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: